中东、非洲地区的脑瘤诊断市场:产业趋势、预测 (～2030年)

中东、非洲地区的脑瘤诊断的市场规模，从2023年到2030年的预测期间内预计以16.9％的年复合成长率成长。

全球脑瘤患者数增加，脑瘤的早期诊断的认识高涨，影像诊断技术的提高，对脑瘤细胞的药物输送技术的创新等要素促进该市场的成长。

本报告提供中东、非洲地区的脑瘤诊断的市场调查，市场概要，市场成长的各种影响因素分析，法律规章情境，市场规模的变化、预测，各种区分、各主要国家的明细，竞争环境，主要企业简介等彙整资讯。

目录

第1章 简介

第2章 中东、非洲地区的脑瘤诊断市场:分类

第3章 摘要整理

第4章 重要考察

• PESTEL分析
• 波特分析

第5章 流行病学

第6章 中东、非洲地区的脑瘤诊断市场:产业考察

第7章 中东、非洲地区的脑瘤诊断市场:法律规章

第8章 市场概要

• 促进因素
• 阻碍因素
• 机会
• 课题

第9章 中东、非洲地区的脑瘤诊断市场:各检验类型

• 概要
• 影像检查
  • 电脑断层扫瞄
  • MRI
  • PET
  • 其他
• 分子检验
• 脑波检验(EEG)
• 腰椎穿刺
• 切片检查
  • 开放式切片检查
  • 定位切片检查
  • 针切片检查
  • 神经科学用内视镜检验
• 其他

第10章 中东、非洲地区的脑瘤诊断市场:各肿瘤类型

• 概要
• 多形性胶芽细胞瘤
• 脑膜瘤
• 星细胞株肿瘤
• 听神经肿瘤
• 乏突起神经胶质瘤
• 其他

第11章 中东、非洲地区的脑瘤诊断市场:各年龄层

• 概要
• 35-65岁
• 65岁以上
• 不满21岁
• 21-34岁

第12章 中东、非洲地区的脑瘤诊断市场:各终端用户

• 概要
• 医院
• 专门诊所
• 诊断中心、研究机关
• 门诊病人手术中心
• 其他

第13章 中东、非洲地区的脑瘤诊断市场:各地区

• 中东、非洲
  • 南非
  • 沙乌地阿拉伯
  • UAE
  • 科威特
  • 埃及
  • 其他

第14章 中东、非洲地区的脑瘤诊断市场:企业形势

• 企业占有率分析:中东、非洲

第15章 SWOT分析

第16章 中东、非洲的脑瘤诊断市场:企业简介

• KONINKLIJKE PHILIPS N.V.
• CANON INC.
• SIEMENS HEALTHCARE GMBH
• BD
• NIHON KOHDEN CORPORATION.
• BIOCEPT, INC.
• BIOMIND
• CEREBRAL DIAGNOSTIC
• DXCOVER LIMITED
• FONAR CORP.
• FUJIFILM CORPORATION
• GE HEALTHCARE.
• HITACHI, LTD.
• MINFOUND MEDICAL SYSTEMS CO.,
• NANTOMICS.
• NEUSOFT CORPORATION
• SEQUOIA HEALTHCARE.
• STERNMED GMBH
• THERMO FISHER SCIENTIFIC INC.
• TIME MEDICAL HOLDING

第17章 问题事项

第18章 相关报告

Middle East & Africa brain cancer diagnostic market is projected to register a substantial CAGR of 16.9 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East & Africa Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, and the rest of the Middle East and Africa), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East & Africa brain cancer diagnostic market are:

Rising cases of brain cancer worldwide

Rising awareness of early diagnosis of brain cancer

Improved imaging techniques

Innovations in drug delivery to brain cancer cells

Market Players

Some of the key market players for the Middle East & Africa brain cancer diagnostic market are listed below:

NIHON KOHDEN CORPORATION.

FUJIFILM Holdings Corporation

GE HealthCare

Koninklijke Philips N.V.

BD

Siemens Healthcare GmbH

Canon Inc.

Others

TABLE OF CONTENTS

1 INTRODUCTION 24

• 1.1 OBJECTIVES OF THE STUDY 24
• 1.2 MARKET DEFINITION 24
• 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET 24
• 1.4 CURRENCY AND PRICING 26
• 1.5 LIMITATIONS 26
• 1.6 MARKETS COVERED 26

2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29

• 2.1 MARKETS COVERED 29
• 2.2 GEOGRAPHICAL SCOPE 30
• 2.3 YEARS CONSIDERED FOR THE STUDY 31
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
• 2.6 MULTIVARIATE MODELLING 36
• 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
• 2.8 DBMR MARKET POSITION GRID 37
• 2.9 VENDOR SHARE ANALYSIS 39
• 2.10 MARKET END USER COVERAGE GRID 40
• 2.11 SECONDARY SOURCES 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 44

• 4.1 PESTEL ANALYSIS 45
• 4.2 PORTER'S FIVE FORCES 46

5 EPIDEMIOLOGY 47

6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48

7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49

• 7.1 REGULATORY SCENARIO IN THE U.S 49
• 7.2 REGULATORY SCENARIO IN AUSTRALIA 50
• 7.3 REGULATORY SCENARIO IN JAPAN 50
• 7.4 REGULATORY SCENARIO IN CHINA 50

8 MARKET OVERVIEW 52

• 8.1 DRIVERS 54
  • 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
  • 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
  • 8.1.3 IMPROVED IMAGING TECHNIQUES 55
  • 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
• 8.2 RESTRAINTS 56
  • 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
  • 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
  • 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
• 8.3 OPPORTUNITIES 57
  • 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
  • 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
  • 8.3.3 RISING HEALTHCARE EXPENDITURE 58
• 8.4 CHALLENGES 59
  • 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
  • 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59

9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60

• 9.1 OVERVIEW 61
• 9.2 IMAGING TEST 64
  • 9.2.1 CT SCAN 65
  • 9.2.2 MRI 65
  • 9.2.3 PET 65
  • 9.2.4 OTHERS 65
• 9.3 MOLECULAR TESTING 66
• 9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
• 9.5 LUMBAR PUNCTURE 67
• 9.6 BIOPSY 68
  • 9.6.1 OPEN BIOPSY 69
  • 9.6.2 STEREOTACTIC BIOPSY 69
  • 9.6.3 NEEDLE BIOPSY 69
  • 9.6.4 NEUROENDOSCOPY 69
• 9.7 OTHERS 69

10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70

• 10.1 OVERVIEW 71
• 10.2 GLIOBLASTOMA MULTIFORME 74
• 10.3 MENINGIOMAS 75
• 10.4 ASTROCYTOMAS 76
• 10.5 ACOUSTIC NEUROMA 77
• 10.6 OLIGODENDROGLIOMA 78
• 10.7 OLIGODENDROGLIOMA 78
• 10.8 OTHERS 79

11 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80

• 11.1 OVERVIEW 81
• 11.2 35-65 84
• 11.3 65 AND ABOVE 85
• 11.4 BELOW 21 86
• 11.5 21-34 87

12 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88

• 12.1 OVERVIEW 89
• 12.2 HOSPITALS 92
• 12.3 SPECIALTY CLINICS 93
• 12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
• 12.5 AMBULATORY SURGICAL CENTERS 95
• 12.6 OTHERS 96

13 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97

• 13.1 MIDDLE EAST AND AFRICA 98
  • 13.1.1 SOUTH AFRICA 105
  • 13.1.2 SAUDI ARABIA 107
  • 13.1.3 U.A.E. 109
  • 13.1.4 KUWAIT 111
  • 13.1.5 EGYPT 113
  • 13.1.6 REST OF MIDDLE EAST AND AFRICA 115

14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 116

• 14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 116

15 SWOT ANALYSIS 117

16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 118

• 16.1 KONINKLIJKE PHILIPS N.V. 118
  • 16.1.1 COMPANY SNAPSHOT 118
  • 16.1.2 REVENUE ANALYSIS 118
  • 16.1.3 COMPANY SHARE ANALYSIS 119
  • 16.1.4 PRODUCT PORTFOLIO 119
  • 16.1.5 RECENT DEVELOPMENTS 120
• 16.2 CANON INC. 121
  • 16.2.1 COMPANY SNAPSHOT 121
  • 16.2.2 REVENUE ANALYSIS 121
  • 16.2.3 COMPANY SHARE ANALYSIS 122
  • 16.2.4 PRODUCT PORTFOLIO 122
  • 16.2.5 RECENT DEVELOPMENT 122
• 16.3 SIEMENS HEALTHCARE GMBH 123
  • 16.3.1 COMPANY SNAPSHOT 123
  • 16.3.2 REVENUE ANALYSIS 124
  • 16.3.3 COMPANY SHARE ANALYSIS 124
  • 16.3.4 PRODUCT PORTFOLIO 125
  • 16.3.5 RECENT DEVELOPMENTS 125
• 16.4 BD 126
  • 16.4.1 COMPANY SNAPSHOT 126
  • 16.4.2 REVENUE ANALYSIS 127
  • 16.4.3 COMPANY SHARE ANALYSIS 127
  • 16.4.4 PRODUCT PORTFOLIO 128
  • 16.4.5 RECENT DEVELOPMENTS 128
• 16.5 NIHON KOHDEN CORPORATION. 129
  • 16.5.1 COMPANY SNAPSHOT 129
  • 16.5.2 RECENT FINANCIALS 129
  • 16.5.3 COMPANY SHARE ANALYSIS 130
  • 16.5.4 PRODUCT PORTFOLIO 130
  • 16.5.5 RECENT DEVELOPMENT 130
• 16.6 BIOCEPT, INC. 131
  • 16.6.1 COMPANY SNAPSHOT 131
  • 16.6.2 REVENUE ANALYSIS 131
  • 16.6.3 PRODUCT PORTFOLIO 132
  • 16.6.4 RECENT DEVELOPMENT 132
• 16.7 BIOMIND 133
  • 16.7.1 COMPANY SNAPSHOT 133
  • 16.7.2 PRODUCT PORTFOLIO 133
  • 16.7.3 RECENT DEVELOPMENT 133
• 16.8 CEREBRAL DIAGNOSTIC 134
  • 16.8.1 COMPANY SNAPSHOT 134
  • 16.8.2 PRODUCT PORTFOLIO 134
  • 16.8.3 RECENT DEVELOPMENT 134
• 16.9 DXCOVER LIMITED 135
  • 16.9.1 COMPANY SNAPSHOT 135
  • 16.9.2 PRODUCT PORTFOLIO 135
  • 16.9.3 RECENT DEVELOPMENT 135
• 16.10 FONAR CORP. 136
  • 16.10.1 COMPANY SNAPSHOT 136
  • 16.10.2 REVENUE ANALYSIS 136
  • 16.10.3 PRODUCT PORTFOLIO 137
  • 16.10.4 RECENT DEVELOPMENT 137
• 16.11 FUJIFILM CORPORATION 138
  • 16.11.1 COMPANY SNAPSHOT 138
  • 16.11.2 REVENUE ANALYSIS 138
  • 16.11.3 PRODUCT PORTFOLIO 139
  • 16.11.4 RECENT DEVELOPMENT 139
• 16.12 GE HEALTHCARE. 140
  • 16.12.1 COMPANY SNAPSHOT 140
  • 16.12.2 REVENUE ANALYSIS 140
  • 16.12.3 PRODUCT PORTFOLIO 141
  • 16.12.4 RECENT DEVELOPMENT 141
• 16.13 HITACHI, LTD. 142
  • 16.13.1 COMPANY SNAPSHOT 142
  • 16.13.2 REVENUE ANALYSIS 142
  • 16.13.3 PRODUCT PORTFOLIO 143
  • 16.13.4 RECENT DEVELOPMENT 143
• 16.14 MINFOUND MEDICAL SYSTEMS CO., 144
  • 16.14.1 COMPANY SNAPSHOT 144
  • 16.14.2 PRODUCT PORTFOLIO 144
  • 16.14.3 RECENT DEVELOPMENT 144
• 16.15 NANTOMICS. 145
  • 16.15.1 COMPANY SNAPSHOT 145
  • 16.15.2 PRODUCT PORTFOLIO 145
  • 16.15.3 RECENT DEVELOPMENT 145
• 16.16 NEUSOFT CORPORATION 146
  • 16.16.1 COMPANY SNAPSHOT 146
  • 16.16.2 REVENUE ANALYSIS 146
  • 16.16.3 PRODUCT PORTFOLIO 147
  • 16.16.4 RECENT DEVELOPMENT 147
• 16.17 SEQUOIA HEALTHCARE. 148
  • 16.17.1 COMPANY SNAPSHOT 148
  • 16.17.2 PRODUCT PORTFOLIO 148
  • 16.17.3 RECENT DEVELOPMENT 148
• 16.18 STERNMED GMBH 149
  • 16.18.1 COMPANY SNAPSHOT 149
  • 16.18.2 PRODUCT PORTFOLIO 149
  • 16.18.3 RECENT DEVELOPMENT 149
• 16.19 THERMO FISHER SCIENTIFIC INC. 150
  • 16.19.1 COMPANY SNAPSHOT 150
  • 16.19.2 REVENUE ANALYSIS 150
  • 16.19.3 PRODUCT PORTFOLIO 151
  • 16.19.4 RECENT DEVELOPMENT 151
• 16.20 TIME MEDICAL HOLDING. 152
  • 16.20.1 COMPANY SNAPSHOT 152
  • 16.20.2 PRODUCT PORTFOLIO 152
  • 16.20.3 RECENT DEVELOPMENTS 152

17 QUESTIONNAIRE 153

18 RELATED REPORTS 156

LIST OF TABLES

• TABLE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 55
• TABLE 2 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 56
• TABLE 3 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 57
• TABLE 4 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 58
• TABLE 5 MIDDLE EAST & AFRICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
• TABLE 6 MIDDLE EAST & AFRICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
• TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
• TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 60
• TABLE 9 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 61
• TABLE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 65
• TABLE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 66
• TABLE 12 MIDDLE EAST & AFRICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
• TABLE 13 MIDDLE EAST & AFRICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 68
• TABLE 14 MIDDLE EAST & AFRICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
• TABLE 15 MIDDLE EAST & AFRICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
• TABLE 16 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 71
• TABLE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 75
• TABLE 18 MIDDLE EAST & AFRICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 76
• TABLE 19 MIDDLE EAST & AFRICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
• TABLE 20 MIDDLE EAST & AFRICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
• TABLE 21 MIDDLE EAST & AFRICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 79
• TABLE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 83
• TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 84
• TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 85
• TABLE 25 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 86
• TABLE 26 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
• TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 88
• TABLE 28 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 94
• TABLE 29 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
• TABLE 30 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
• TABLE 31 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
• TABLE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 95
• TABLE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 95
• TABLE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 96
• TABLE 35 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
• TABLE 36 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
• TABLE 37 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
• TABLE 38 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 98
• TABLE 39 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 98
• TABLE 40 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 98
• TABLE 41 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
• TABLE 42 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
• TABLE 43 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
• TABLE 44 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 100
• TABLE 45 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 100
• TABLE 46 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 100
• TABLE 47 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
• TABLE 48 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
• TABLE 49 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
• TABLE 50 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 102
• TABLE 51 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 102
• TABLE 52 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 102
• TABLE 53 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
• TABLE 54 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
• TABLE 55 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
• TABLE 56 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 104
• TABLE 57 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 104
• TABLE 58 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 104
• TABLE 59 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
• TABLE 60 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
• TABLE 61 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
• TABLE 62 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 106
• TABLE 63 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 106
• TABLE 64 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 106
• TABLE 65 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107

LIST OF FIGURES

• FIGURE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 20
• FIGURE 2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 23
• FIGURE 3 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 24
• FIGURE 4 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 25
• FIGURE 5 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 25
• FIGURE 6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 26
• FIGURE 7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 28
• FIGURE 8 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 30
• FIGURE 9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 31
• FIGURE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 34
• FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 35
• FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 35
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET 44
• FIGURE 14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 52
• FIGURE 15 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 53
• FIGURE 16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 53
• FIGURE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 54
• FIGURE 18 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 62
• FIGURE 19 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 63
• FIGURE 20 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 63
• FIGURE 21 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 64
• FIGURE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 72
• FIGURE 23 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 73
• FIGURE 24 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 73
• FIGURE 25 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 74
• FIGURE 26 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 80
• FIGURE 27 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 81
• FIGURE 28 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 81
• FIGURE 29 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 82
• FIGURE 30 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 90
• FIGURE 31 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 91
• FIGURE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 91
• FIGURE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 92
• FIGURE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 92
• FIGURE 35 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 107